APLIF.US Appili Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0020 USD
Close of Nov 14, 2026
0.0020 0.0200
Market cap
USD 265K
P/E
-
P/B
1.48x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is APLIF.US undervalued?

Graham number

The Graham number of Appili Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Appili Therapeutics Inc fundamental analysis

No fundamental analysis for Appili Therapeutics Inc yet.

Appili Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Appili Therapeutics Inc

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishma…

Full company profile